Product Code: TMRGL30530
Induced Pluripotent Stem Cells Market - Scope of Report
TMR's report on the global induced pluripotent stem cells market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global induced pluripotent stem cells market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global induced pluripotent stem cells market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the induced pluripotent stem cells market.
Market Snapshot |
Market Value in 2023 | US$ 1.7 Bn |
Market Value in 2034 | US$ 4.6 Bn |
CAGR | 9.4% |
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global induced pluripotent stem cells market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global induced pluripotent stem cells market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global induced pluripotent stem cells market.
The report delves into the competitive landscape of the global induced pluripotent stem cells market. Key players operating in the global induced pluripotent stem cells market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global induced pluripotent stem cells market profiled in this report.
Key Questions Answered in Global induced pluripotent stem cells Market Report:
- What is the sales/revenue generated by induced pluripotent stem cells across all regions during the forecast period?
- What are the opportunities in the global induced pluripotent stem cells market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2034?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Induced Pluripotent Stem Cells Market - Research Objectives and Research Approach
The comprehensive report on the global induced pluripotent stem cells market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global induced pluripotent stem cells market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global induced pluripotent stem cells market.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Induced Pluripotent Stem Cells Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Induced Pluripotent Stem Cells Market Analysis and Forecast, 2020-2034
5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product /Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Cell Type
- 6.1. Introduction & Definition
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Cell Type, 2020-2034
- 6.3.1. Hepatocytes
- 6.3.2. Fibroblasts
- 6.3.3. Keratinocytes
- 6.3.4. Others (Neurons, etc.)
- 6.4. Market Attractiveness Analysis, by Cell Type
7. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Application
- 7.1. Introduction & Definition
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Application, 2020-2034
- 7.3.1. Drug Development
- 7.3.2. Regenerative Medicine
- 7.3.3. Toxicity Testing
- 7.3.4. Tissue Engineering
- 7.3.5. Cell Therapy
- 7.3.6. Disease Modeling
- 7.4. Market Attractiveness Analysis, by Application
8. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by End-user
- 8.1. Introduction & Definition
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, by End-user, 2020-2034
- 8.3.1. Hospitals
- 8.3.2. Diagnostic Centers
- 8.3.3. Pharmaceutical & Biotechnology Companies
- 8.3.4. Contract Research Organizations
- 8.3.5. Others (Academic & Research Institutes, etc.)
- 8.4. Market Attractiveness Analysis, by End-user
9. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Region
- 9.1. Key Findings
- 9.2. Market Value Forecast, by Region, 2020-2034
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
- 9.3. Market Attractiveness Analysis, by Region
10. North America Induced Pluripotent Stem Cells Market Analysis and Forecast
- 10.1. Introduction
- 10.2. Key Findings
- 10.3. Market Value Forecast, by Cell Type, 2020-2034
- 10.3.1. Hepatocytes
- 10.3.2. Fibroblasts
- 10.3.3. Keratinocytes
- 10.3.4. Others (Neurons, etc.)
- 10.4. Market Value Forecast, by Application, 2020-2034
- 10.4.1. Drug Development
- 10.4.2. Regenerative Medicine
- 10.4.3. Toxicity Testing
- 10.4.4. Tissue Engineering
- 10.4.5. Cell Therapy
- 10.4.6. Disease Modeling
- 10.5. Market Value Forecast, by End-user, 2020-2034
- 10.5.1. Hospitals
- 10.5.2. Diagnostic Centers
- 10.5.3. Pharmaceutical & Biotechnology Companies
- 10.5.4. Contract Research Organizations
- 10.5.5. Others (Academic & Research Institutes, etc.)
- 10.6. Market Value Forecast, by Country, 2020-2034
- 10.6.1. U.S.
- 10.6.2. Canada
- 10.7. Market Attractiveness Analysis
- 10.7.1. By Cell Type
- 10.7.2. By Application
- 10.7.3. By End-user
- 10.7.4. By Country
11. Europe Induced Pluripotent Stem Cells Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Key Findings
- 11.3. Market Value Forecast, by Cell Type, 2020-2034
- 11.3.1. Hepatocytes
- 11.3.2. Fibroblasts
- 11.3.3. Keratinocytes
- 11.3.4. Others (Neurons, etc.)
- 11.4. Market Value Forecast, by Application, 2020-2034
- 11.4.1. Drug Development
- 11.4.2. Regenerative Medicine
- 11.4.3. Toxicity Testing
- 11.4.4. Tissue Engineering
- 11.4.5. Cell Therapy
- 11.4.6. Disease Modeling
- 11.5. Market Value Forecast, by End-user, 2020-2034
- 11.5.1. Hospitals
- 11.5.2. Diagnostic Centers
- 11.5.3. Pharmaceutical & Biotechnology Companies
- 11.5.4. Contract Research Organizations
- 11.5.5. Others (Academic & Research Institutes, etc.)
- 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Cell Type
- 11.7.2. By Application
- 11.7.3. By End-user
- 11.7.4. By Country/Sub-region
12. Asia Pacific Induced Pluripotent Stem Cells Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Key Findings
- 12.3. Market Value Forecast, by Cell Type, 2020-2034
- 12.3.1. Hepatocytes
- 12.3.2. Fibroblasts
- 12.3.3. Keratinocytes
- 12.3.4. Others (Neurons, etc.)
- 12.4. Market Value Forecast, by Application, 2020-2034
- 12.4.1. Drug Development
- 12.4.2. Regenerative Medicine
- 12.4.3. Toxicity Testing
- 12.4.4. Tissue Engineering
- 12.4.5. Cell Therapy
- 12.4.6. Disease Modeling
- 12.5. Market Value Forecast, by End-user, 2020-2034
- 12.5.1. Hospitals
- 12.5.2. Diagnostic Centers
- 12.5.3. Pharmaceutical & Biotechnology Companies
- 12.5.4. Contract Research Organizations
- 12.5.5. Others (Academic & Research Institutes, etc.)
- 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Cell Type
- 12.7.2. By Application
- 12.7.3. By End-user
- 12.7.4. By Country/Sub-region
13. Latin America Induced Pluripotent Stem Cells Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Key Findings
- 13.3. Market Value Forecast, by Cell Type, 2020-2034
- 13.3.1. Hepatocytes
- 13.3.2. Fibroblasts
- 13.3.3. Keratinocytes
- 13.3.4. Others (Neurons, etc.)
- 13.4. Market Value Forecast, by Application, 2020-2034
- 13.4.1. Drug Development
- 13.4.2. Regenerative Medicine
- 13.4.3. Toxicity Testing
- 13.4.4. Tissue Engineering
- 13.4.5. Cell Therapy
- 13.4.6. Disease Modeling
- 13.5. Market Value Forecast, by End-user, 2020-2034
- 13.5.1. Hospitals
- 13.5.2. Diagnostic Centers
- 13.5.3. Pharmaceutical & Biotechnology Companies
- 13.5.4. Contract Research Organizations
- 13.5.5. Others (Academic & Research Institutes, etc.)
- 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Cell Type
- 13.7.2. By Application
- 13.7.3. By End-user
- 13.7.4. By Country/Sub-region
14. Middle East & Africa Induced Pluripotent Stem Cells Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Key Findings
- 14.3. Market Value Forecast, by Cell Type, 2020-2034
- 14.3.1. Hepatocytes
- 14.3.2. Fibroblasts
- 14.3.3. Keratinocytes
- 14.3.4. Others (Neurons, etc.)
- 14.4. Market Value Forecast, by Application, 2020-2034
- 14.4.1. Drug Development
- 14.4.2. Regenerative Medicine
- 14.4.3. Toxicity Testing
- 14.4.4. Tissue Engineering
- 14.4.5. Cell Therapy
- 14.4.6. Disease Modeling
- 14.5. Market Value Forecast, by End-user, 2020-2034
- 14.5.1. Hospitals
- 14.5.2. Diagnostic Centers
- 14.5.3. Pharmaceutical & Biotechnology Companies
- 14.5.4. Contract Research Organizations
- 14.5.5. Others (Academic & Research Institutes, etc.)
- 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Cell Type
- 14.7.2. By Application
- 14.7.3. By End-user
- 14.7.4. By Country/Sub-region
15. Competition Landscape
- 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
- 15.2. Market Share Analysis, by Company (2023)
- 15.3. Company Profiles
- 15.3.1. Axol Bioscience
- 15.3.1.1. Company Overview
- 15.3.1.2. Product Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Financial Overview
- 15.3.1.5. Strategic Overview
- 15.3.2. Cynata Therapeutics Limited
- 15.3.2.1. Company Overview
- 15.3.2.2. Product Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Financial Overview
- 15.3.2.5. Strategic Overview
- 15.3.3. Evotec SE
- 15.3.3.1. Company Overview
- 15.3.3.2. Product Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Financial Overview
- 15.3.3.5. Strategic Overview
- 15.3.4. Fate Therapeutics
- 15.3.4.1. Company Overview
- 15.3.4.2. Product Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Financial Overview
- 15.3.4.5. Strategic Overview
- 15.3.5. FUJIFILM Cellular Dynamics, Inc.
- 15.3.5.1. Company Overview
- 15.3.5.2. Product Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Financial Overview
- 15.3.5.5. Strategic Overview
- 15.3.6. Ncardia
- 15.3.6.1. Company Overview
- 15.3.6.2. Product Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Financial Overview
- 15.3.6.5. Strategic Overview
- 15.3.7. LizarBio Therapeutics
- 15.3.7.1. Company Overview
- 15.3.7.2. Product Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Financial Overview
- 15.3.7.5. Strategic Overview
- 15.3.8. REPROCELL Global
- 15.3.8.1. Company Overview
- 15.3.8.2. Product Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Financial Overview
- 15.3.8.5. Strategic Overview
- 15.3.9. Sumitomo Dainippon Pharma Company Limited
- 15.3.9.1. Company Overview
- 15.3.9.2. Product Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Financial Overview
- 15.3.9.5. Strategic Overview
- 15.3.10. Takara Bio USA, Inc.
- 15.3.10.1. Company Overview
- 15.3.10.2. Product Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Financial Overview
- 15.3.10.5. Strategic Overview
- 15.3.11. Thermo Fisher Scientific
- 15.3.11.1. Company Overview
- 15.3.11.2. Product Portfolio
- 15.3.11.3. SWOT Analysis
- 15.3.11.4. Financial Overview
- 15.3.11.5. Strategic Overview
- 15.3.12. Vertex Pharmaceuticals
- 15.3.12.1. Company Overview
- 15.3.12.2. Product Portfolio
- 15.3.12.3. SWOT Analysis
- 15.3.12.4. Financial Overview
- 15.3.12.5. Strategic Overview